Intratumoral dose heterogeneity promotes adaptive anti-tumor immunity and predicts clinical response to radiopharmaceutical therapy
Maya E. Takashima, Ohyun Kwon, Zachary Ells, Vincent R. Li, Charlotte Sawicki, Rene Welch Schwartz, Shin Hye Ahn, Hyun Meredith, Malick Bio Idrissou, Tracy J. Berg, Paul A. Clark, Michael J. Lawless, Abby Besemer, Tyler Bradshaw, Scott B. Perlman, , Zachary Scott Morris
This study shows that heterogeneous radiation dose in tumors enhances anti-tumor immunity and correlates with better clinical outcomes in prostate cancer patients.
bioRxiv · Jul 30, 2026 · PreprintCancer Biology